Surgery remains the initial treatment for patients with early-stage non-small cell lung cancer (NSCLC). The frequent occurrence of distant metastases and local regional failure after surgical resection would indicate that additional treatment is necessary. Early trials of adjuvant chemotherapy and postoperative radiation were often plagued by small patient sample size, inadequate surgical staging, and ineffective or antiquated treatment. A 1995 meta-analysis found a nonsignificant reduction in risk of death for postoperative cisplatin-based chemotherapy. This was followed by a new generation of randomized phase III trials some of which have reported a benefit for chemotherapy in the adjuvant setting. Based on the results of these trials, platin-based chemotherapy has become the standard of care for resected stages II and IIIA NSCLC. The role of postoperative radiation therapy remains to be defined. In the future, improvement in survival outcomes from adjuvant treatment is likely to result from the evaluation of novel agents, identification of tumor markers predictive of disease relapse, and definition of factors that determine sensitivity to therapeutic agents. Some of the molecularly targeted agents such as the angiogenesis and epidermal growth factor receptor inhibitors are being incorporated into clinical trials. Gene expression profiles and proteomics are techniques being used to create prediction models to identify patients at risk for disease relapse. Molecular markers such as ERCC1 may determine response to treatment. Increasing the understanding of the molecular makeup of lung cancer will hopefully increase cure rates for patients by maximizing the efficacy of the adjuvant therapy.
Introduction
Lung cancer remains one of the leading causes of cancer deaths worldwide. Surgery is the standard of care for the treatment of early stage non-small cell lung cancer (NSCLC) but less than one-third of patients present with disease that is potentially resectable. Clinical staging has improved with the use of positron emission tomography and this alone may result in stage migration and an apparent improvement in survival for early stage resected NSCLC. However, outcome is closely linked to the pathologic stage therefore, it is of utmost importance that intra-operative staging be performed especially adequate lymph node sampling. Surgery, however, is an imperfect therapy and 5-year survival rates have been disappointing because of distant and local recurrences (Table 1) [Mountain, 1997] .
Distant metastases after surgery largely account for treatment failure and patient mortality from NSCLC. Adjuvant chemotherapy after surgical resection would appear to be the logical approach in order to reduce disease recurrence and improve survival. The need for adjuvant chemotherapy was recognized in the 1960s and 1970s. These early adjuvant trials utilized immunotherapy (bacillus Calmette-Guerin), alkylating agents, and/or radiotherapy but they were plagued by inaccurate staging, inadequate surgery, insufficient sample size, and inferior adjuvant treatment. In the late 1970s, the Lung Cancer Study Group (LCSG) conducted a number of trials that required that patients undergo rigorous mediastinal lymph node sampling, which allowed for proper stratification and survival analysis [Feld et al. 1993; Lad et al. 1988; Holmes et al. 1986] . These studies were able to demonstrate an improvement in disease-free and median survival rates favoring adjuvant therapy but were not able to show an overall survival benefit for the treated patients. A metaanalysis published in 1995 examined the results of randomized trials of surgery compared with surgery plus chemotherapy conducted between 1965 and 1991 [Non-Small Cell Lung Cancer Collaborative Group, 1995 . Treatment with cisplatin-based chemotherapy resulted in a hazard ratio (HR) of 0.87 (p ¼ 0.08) with a 13% reduction in death supporting adjuvant therapy. This analysis did not justify the routine use of postoperative therapy, but renewed an interest in pursuing adjuvant trials in early stage NSCLC. Currently, the results from several randomized clinical trials now support the use of adjuvant chemotherapy after surgical resection. This article will review the data from these modern trials and discuss the future direction of research in this area.
Modern adjuvant trials
In the last 10 years, the results from a new generation of adjuvant trials have been reported. In general these trials had more consistent surgical staging and have usually employed platinumbased chemotherapy ( Table 2 ).
The first reported study was the North American Intergroup Trial (INT0115, ECOG 3590) [Keller et al. 2000 ]. Patients with stages II and IIIA NSCLC were randomized to receive radiotherapy or concurrent chemoradiotherapy after surgery. This trial was unique in that all patients received postoperative radiotherapy and the adjuvant chemotherapy was delivered concurrent with the radiation. There were no differences between the patient groups with regard to survival and patterns of recurrence. There was more toxicity on the concurrent arm of the study, which may have accounted for the lack of efficacy on this trial particularly for the stage II patients. It is important to note that scientific correlative studies were included as part of the study design to explore the impact of molecular markers, p53 and K-ras, on patient outcome [Schiller et al. 2001] . Tumors from 197 patients were analyzed. Neither p53 mutations, p53 protein expression, or K-ras mutations correlated with survival or progression-free survival.
The Adjuvant Lung Project Italy (ALPI) was probably the first adequately powered trial enrolling over 1200 participants [Scagliotti et al. 2003 ]. Patients with stages IIIIA were randomized to receive MVP (mitomycin, vindesine, cisplatin) or observation. Postoperative radiotherapy was allowed. The trial was terminated early because of slow accrual during the last several months. There was no significant difference in overall survival between the study arms (HR 0.96, 95% CI: 0.811.13, p ¼ 0.589). Problems with chemotherapy delivery and toxicity may have accounted for the lack of benefit for the adjuvant chemotherapy. An exploratory analysis of molecular markers p53, Ki67, and K-ras was conducted in available tumor tissue but no association was established with stage, histology, or survival.
The Big Lung Trial (BLT) evaluated cisplatinbased chemotherapy in a number of treatment situations [Waller et al. 2004] . Patients with stages IIIIA NSCLC were randomly assigned to cisplatin-based neoadjuvant/adjuvant chemotherapy or surgery alone. Not all of the patients had complete surgical resections or were able to complete chemotherapy. There was no difference in overall survival between the study arms but this trial was not designed to specifically evaluate adjuvant chemotherapy, therefore it was underpowered to detect a significant survival difference.
The International Adjuvant Lung Cancer Trial (IALT) was a landmark study that initially justified the use of adjuvant chemotherapy in resected NSCLC [The International Adjuvant Lung Cancer Trial Collaborative Group, 2004] . This trial employed a 'user friendly' study design allowing the treating institution to make the decisions regarding the cisplatin dose, the drug combined with cisplatin, and the administration of postoperative radiation therapy. Over 1800 patients with stages IIIIA resected NSCLC received three to four cycles of cisplatin-based chemotherapy or observation. The primary endpoint was survival and a 5% absolute improvement in survival was anticipated. The 5-year survival (44.5% versus IA  TIN0  67  10  15  IB  T2N0  57  10  30  IIA  T1N1  55  IIB  T2N1  39  12  40  T3N0  38  IIIA  T3N1  25  15  60  T1-3N2  23 40.4%, HR 0.86, p < 0.03) and disease-free survival (p < 0.003) was significantly higher for the patients treated with chemotherapy. The toxicity was acceptable and benefit was seen for all disease stages with the most survival advantage being in stage IIIA. After an additional follow up of 3 years, the results of the IALT were re-evaluated [Le Chevalier et al. 2008] . Interestingly, the survival and disease-free survival benefit was no longer apparent for the adjuvant population. This was thought to be secondary to an increased number of non-lung cancer deaths in the patients who had received postoperative chemotherapy, indicating the importance of long-term follow up.
The National Cancer Institute of Canada (NCIC) Intergroup trial JBR.10 was conducted in patients with stages IB and II resected NSCLC randomized to receive four courses of cisplatin and vinorelbine or observation [Winton et al. 2005] .
Overall survival was significantly prolonged in the chemotherapy group (94 versus 73 months, HR 0.69, p ¼ 0.04) as was relapse-free survival (HR 0.60, p < 0.001), and 5-year survival (69 versus 54%, p ¼ 0.03). A subgroup analysis indicated that the significant survival benefit was only seen in patients with stage II disease (p ¼ 0.004).
The results of long-term follow up of this trial are anticipated in the near future.
The Adjuvant Navelbine International Trialist Association (ANITA) reported a randomized trial in patients with resected stages IBIIIA NSCLC [Douillard et al. 2006 ]. As in JBR.10, the chemotherapy employed was cisplatin and vinorelbine. Postoperative radiation was allowed.
For the patients treated with chemotherapy there was a significant improvement in overall survival (65.7 versus 43.7 months, HR 0.80, p ¼ 0.017). Survival at 5 years improved by 8.6% with chemotherapy and was maintained at 7 years. A subset analysis did not show a survival benefit for adjuvant chemotherapy in stage IB patients.
The Lung Adjuvant Cisplatin Evaluation (LACE) was a meta-analysis of the last five described trials [Pignon et al. 2008 ]. The overall HR of death was 0.89 (p ¼ 0.005) corresponding to a 5-year absolute benefit of 5.4% from chemotherapy. Benefit varied with stage (HR for IA ¼ 1.40, IB ¼ 0.93, II ¼ 0.83, III ¼ 0.83) but not with type or dose of chemotherapy. The only other parameter that predicted for a higher chemotherapy effect was better performance status.
Cancer and Leukemia Group B (CALGB) 9633 was a unique trial because it included only patients with resected stage IB NSCLC and carboplatin-based chemotherapy was utilized as adjuvant treatment [Strauss et al. 2008 ]. The trial was stopped early after 344 patients were accrued when a predetermined survival endpoint was met. Chemotherapy compliance was very good and toxicity was low. When the results of the trial were initially reported with a median follow-up of 34 months, the 4-year (71 versus 59%, HR 0.62, p ¼ 0.028) and failure-free (p ¼ 0.035) survivals significantly favored chemotherapy [Strauss et al. 2004 ] however, with longer follow up the overall survival (HR 0.83, 90% CI: 0.641.08, p ¼ 0.12) no longer favored adjuvant chemotherapy [Strauss et al. 2008 ]. The results of the CALGB trial bring up two contentious issues. The first is with regard to the adjuvant treatment of patients with stage IB NSCLC. The LACE meta-analysis indicated that the benefit for stage IB was very modest (HR 0.93). A subset analysis of the CALGB trial indicated a survival benefit for patients with tumors 4 cm who received adjuvant treatment (HR 0.69, p ¼ 0.043). These data suggest that select patients with stage IB NSCLC may actually benefit from adjuvant treatment and this group should continue to be included in clinical trials.
The second issue has to do with the choice of the platinum (cisplatin or carboplatin) for treatment in the adjuvant situation. The CISCA meta-analysis evaluated cisplatin versus carboplatin-based chemotherapy in advanced NSCLC [Ardizzoni et al. 2007 ]. There was a slight survival benefit for cisplatin-based chemotherapy which became significant in patients treated with nonsquamous histology and those treated with third-generation chemotherapeutic agents. Although this analysis was in advanced NSCLC the demonstration of a slight survival advantage for cisplatin may be of more importance in a curative situation, that is, adjuvant chemotherapy.
Although most of the trials discussed thus far utilize platin-based chemotherapy, it is worthwhile mentioning the adjuvant studies conducted in Japan employing UFT, an oral fluoropyrimidine.
A meta-analysis of postoperative UFT trials demonstrated that adjuvant therapy with UFT significantly improved overall survival with an HR 0.74 (95% CI: 0.610.88, p ¼ 0.001) [Hamada et al. 2005 ]. To date, there has been no confirmatory evidence outside of Japan supporting the use of UFT in the adjuvant setting.
Neoadjuvant chemotherapy
The concept of delivering neoadjuvant chemotherapy prior to surgical resection in NSCLC has some potential advantages including: tumor downstaging, early treatment of micrometastases, better chemotherapy delivery, and an in vivo assessment of chemotherapy sensitivity. There are two small trials that randomly assigned patients with potentially resectable IIIA NSCLC to receive preoperative chemotherapy or surgery alone [Rosell et al. 1999; Roth et al. 1998 ]. In both instances, survival was significantly improved in the chemotherapy group without an increase in surgical morbidity and mortality indicating that pre-operative chemotherapy is a feasible approach.
The French Thoracic Cooperative Group conducted a phase III trial in patients with stages IBIIIA NSCLC [Depierre et al. 2002] . Patients were randomized to pre-operative mitomycin, ifosfamide, and cisplatin or surgery alone. Stage III patients received postoperative radiotherapy. There was a nonsignificant 11-month improvement in median survival for the chemotherapy group (37 versus 26 months, p ¼ 0.15) with a slight increase in postoperative mortality (6.7 versus 4.5%). Treatment benefit was confined to N0 and N1 disease.
The Bimodality Lung Oncology Team (BLOT) trial was a phase II study that demonstrated the feasibility of neoadjuvant carboplatin/paclitaxel chemotherapy [Pisters et al. 2000 ]. The following phase III trial, Southwest Oncology Group (SWOG) 9900 randomly assigned patients with stages IBIIIA (T3N1) to receive three cycles of pre-operative carboplatin/paclitaxel or surgery alone [Pisters et al. 2005 ]. The trial closed prematurely because of the emerging data showing a survival benefit for adjuvant chemotherapy making it unethical to continue a surgeryalone arm. Although survival appears to favor neoadjuvant chemotherapy, the study may be underpowered to show a significant advantage for pre-operative treatment. A similar situation occurred with another randomized Phase III study, Ch.E.S.T. (Chemotherapy for Early Stages Trial) [Scagliotti et al. 2008b ]. Benefit for pre-operative chemotherapy was seen in stages IIBIIIA but outcome was likely affected by early termination of the trial. A meta-analysis of 12 randomized pre-operative chemotherapy trials demonstrated a survival benefit for chemotherapy with a hazard ratio of 0.82 [Burdett et al. 2006 ]. This survival advantage is similar to what is seen with chemotherapy delivered after surgery.
The use of neoadjuvant chemotherapy remains a feasible, albeit unproven, approach to the treatment of early-stage NSCLC. The NATCH trial could answer the question regarding optimal timing of chemotherapy in early-stage NSCLC.
It is a three-arm randomized study comparing neoadjuvant and adjuvant carboplatin/pactlitaxel to surgery alone. The results will be presented at the 2009 American Society of Clinical Oncology annual meeting.
Postoperative radiation therapy (PORT)
The current role of PORT has been largely defined by the PORT meta-analysis [PORT Meta-analysis Trialists ' Group, 1998 ]. This analysis included the data of 2128 patients from nine randomized studies dating from 1965. The results indicated that there was a detrimental effect on overall survival (HR 1.21, 95% CI: 1.081.34). Subgroup analyses suggested that this adverse effect was restricted to patients with stage I/II disease with no adverse effect noted in stage III patients. Radiation technology and lung cancer staging have clearly improved since the publication of the PORT meta-analysis. It is possible that modern PORT may not result in a detrimental effect. Unfortunately, there is a lack of randomized studies to adequately evaluate its role utilizing current treatment standards.
The primary importance of thoracic radiotherapy is in the reduction of local-regional relapse.
In patients with stages I and II disease after adequate surgery the risk is low. It has been suggested that the inclusion of PORT in the INT0115 (E3590) and ALPI trials may have contributed to the negative results and lack of benefit for adjuvant chemotherapy. In stage III disease, local recurrence can be greater than 30% in patients treated with surgery alone [The Lung Cancer Study Group, 1986 ]. The PORT meta-analysis and several retrospective studies suggest that patients with stage III NSCLC may potentially derive a survival advantage from the use of PORT [Machtay et al. 2001; Sawyer et al. 1997] . A subset analysis of the ANITA trial found that patients with mediastinal lymph node (N2) involvement had better outcomes with PORT. The median survival of N2 patients who received chemotherapy alone after surgery was 23.8 months as compared to 47.4 months for the patients who also received PORT. This survival advantage was not seen in patients with lower stage disease [Douillard et al. 2006 ].
Currently, PORT may be considered for patients with stage III disease who have inadequate mediastinal lymph node evaluation, multistation disease, or extracapsular nodal extension in order to reduce local-regional recurrence. The radiation should be given sequentially following adjuvant chemotherapy since there is no evidence that concurrent treatment is beneficial in resected stage III patients. The Lung Adjuvant Radiotherapy Trial (LungART) which is being conducted by the EORTC is designed to evaluate PORT in patients with N2 disease.
Future directions: novel agents, new trials and customizing treatment
The benefits of adjuvant therapy remain modest, with improvements in 5-year survival of only 515% indicating the inadequacy of current available treatment. It is also clear that some NSCLC patients do not need adjuvant therapy after surgical resection. Thus, there is a need not only to improve the survival outcomes of surgically resected patients but also to develop better predictive markers of relapse. Further innovations in adjuvant therapy are therefore likely to result from evaluation of novel agents, improved identification of tumor markers predictive of relapse, and a better understanding of factors that determine sensitivity to therapeutic agents.
Novel agents
Pemetrexed is a multitargeted antifolate that has been approved for the first-line treatment of NSCLC. In a recent randomized Phase III trial it was combined with cisplatin and compared to cisplatin/gemcitabine in the treatment of advanced NSCLC [Scagliotti et al. 2008a ]. The overall outcome for both doublets was similar however, the pemetrexed combination was significantly better in patients with nonsquamous histology. The pemetrexed/cisplatin doublet is currently being including in adjuvant trials for patients with resected nonsquamous NSCLC.
Greater insight into the molecular processes involved in carcinogenesis and cancer progression has led to the development of drugs that target relevant molecular pathways. Initial evaluations in the management of NSCLC have focused on drugs targeting vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR).
Tumor angiogenesis is recognized as a critical component of tumor growth and metastasis and the VEGF pathway plays a pivotal role in normal and tumor angiogenesis [Hicklin and Ellis, 2005; Ferrara, 2002] . VEGF overexpression has been shown to be associated with relapse following surgery and poor prognosis in NSCLC [Yuan et al. 2001; Fontanini et al. 1997 ]. Based on its central role in tumor angiogenesis, drugs targeting VEGF are being developed for the treatment of many cancers.
Bevacizumab is a humanized monoclonal antibody to VEGF that effectively prevents it from binding to its receptors. Bevacizumab was evaluated in combination with carboplatin/paclitaxel in advanced NSCLC patients in a phase II trial . Concerns were raised regarding the incidence of pulmonary hemorrhage in patients with squamous histology, so these patients were excluded from the Phase III trial that followed. Exclusions also included patients with brain metastases, history of hemoptysis or recent thrombotic episodes, and those on anticoagulation. Eastern Cooperative Oncology Group trial, E4599 randomized advanced NSCLC patients to receive carboplatin/paclitaxel± bevacizumab [Sandler et al. 2006 ]. The addition of bevacizumab improved median overall survival (12.3 versus 10.3 months) and progression-free survival (6.2 versus 4.5 months). There was greater toxicity in the bevacizumab arm, specifically hemorrhage (4.4 versus 0.7%), neutropenia (25.5 versus 16.8%), and thrombocytopenia (1.6 versus 0.2%).
In another phase III study, the AVAiL trial, the addition of bevacizumab to cisplatin/gemcitabine improved the primary endpoint of progression free survival but did not improve overall survival [Reck et al. 2009 ]. Based on the data in advanced NSCLC, a phase III adjuvant trial, E1505, is currently underway randomizing patients with resected NSCLC to receive chemothera-py±bevacizumab. The chemotherapy is restricted to cisplatin-based regimens including cisplatin/ pemetrexed for nonsquamous histologies. Patients with squamous cell histology are allowed in this trial since the primary tumor is resected prior to chemotherapy thus eliminating a potential source for tumor-related hemorrhage. The proposed objective is to detect a 25% improvement in median survival in patients receiving bevacizumab. Despite the excitement regarding this trial there remains a sense of caution with the use of anti-VEGF therapy in the postoperative setting. There may be concerns regarding postoperative healing and toxicities such as hemorrhage, neutropenic fever, hypertension, and thrombotic episodes. In addition, the long-term toxicities of a year of bevacizumab are unknown and will be defined by this trial. These toxicities may be viewed differently by both treating physicians and patients in the adjuvant setting as compared to the advanced disease situation. New agents targeting the various VEGF receptors are in development and hopefully they will be less toxic alternatives if proven to be efficacious in lung cancer treatment.
Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is expressed in many NSCLCs and is involved in many aspects of cancer formation and progression [Arteaga, 2003] . Inhibitors of EGFR tyrosine kinase (EGFR-TKIs), erlotinib and gefitinib, have been evaluated in the management of NSCLC [Perez-Soler et al. 2004; Fukuoka et al. 2003; Kris et al. 2003 ]. Erlotinib subsequently was approved for the treatment of relapsed NSCLC based on the results of a placebo-controlled randomized study demonstrating a survival benefit with the use of erlotinib [Shepherd et al. 2005] . Data from clinical trials of EGFR-TKIs suggest that patients with certain clinical characteristics such as adenocarcinoma histology, female gender, Asian ethnicity, and nonsmoking status had a higher likelihood of clinical benefit Miller et al. 2004] . Retrospective analyses of tumors of patients responding to these agents revealed that the presence of activating mutations in the tyrosine kinase domain of the EGFR gene predicts for response and clinical benefit from EGFR-TKIs [Lynch et al. 2004; Paez et al. 2004 ]. Subsequently, other investigators have suggested that increased EGFR gene copy number and EGFR expression may be more predictive of benefit from EGFR-TKIs [Cappuzzo et al. 2005] . The relative importance of each factor in predicting benefit from these agents remains to be determined in prospective clinical trials.
Based on the observation that EGFR expression by immunohistochemistry and increased EGFR gene copy number may predict for increased survival with EGFR-TKIs in relapsed NSCLC patients, a clinical trial, called the RADIANT trial, evaluating the role of erlotinib in patients with EGFR-positive (IHC and/or FISH) tumors is currently ongoing. Patients are allowed to receive adjuvant chemotherapy and then randomized to erlotinib or placebo. Gefitinib has been studied in earlier stage NSCLC. In a NCIC trial, JBR.19, patients with resected NSCLC were allowed to receive adjuvant chemotherapy and then went on to receive geftinib or placebo. The trial was terminated after the release of negative results from the ISEL trial, which showed no survival advantage for gefitinib in advanced-stage NSCLC [Thatcher et al. 2005] . The results of the NCIC study have not yet been released. The RADIANT trial and other such prospective studies will potentially define the role of EGFR-TKIs in the adjuvant therapy of NSCLC and until these results are available these agents should not be used in the adjuvant setting in unselected patients.
MAGE-A3 (melanoma antigen family A, 3) is expressed in many human cancers including lung cancer [Sienel et al. 2004 ]. The MAGRIT trial is an ongoing Phase III study evaluating GSK1572932A, an antigen-specific (MAGE-A3) cancer immune therapeutic, as adjuvant therapy in patients with resected NSCLC. The tumors must express MAGE-A3 as an eligibility criteria for trial entry.
Tumor factors predictive of relapse
Decisions regarding the administration of adjuvant treatment in NSCLC patients are based primarily on the stage of the disease. The biologic factors that regulate metastases and relapse have not been further characterized. Systematic genomic and proteomic evaluation of lung cancers may yield information regarding risk of relapse and thus lead to better prognostic assessments. Recently Potti and colleagues reported the results of assessing gene expression patterns in stratifying risk in NSCLC patients [Potti et al. 2006 ]. The investigators utilized gene expression profiles of tumors to generate a lung metagene model predictive of recurrence. When compared to clinical prognostic variables, the lung metagene model was significantly better in predicting recurrence for individual patients including identifying stage IA patients at risk for relapse. Based on these data, CALGB is planning a clinical trial that will stratify patients with stage IA NSCLC based on the lung metagene model to high and low risk of relapse. Patients at low risk will be observed and those at high risk will be randomized to observation or chemotherapy.
Evaluation of proteins in cancer cells can provide information not obtained by the genetic profile. The genetic alterations that lead to a malignant phenotype manifest through protein expression. Assessment of the proteome profile of the tumor could be a tool for both diagnostic and prognostic purposes. Recently Kikuchi and colleagues presented the results of the proteomic analysis of lung cancer tumors [Kikuchi et al. 2006 ]. The protein profiles of 175 lung cancers and 62 histologically normal lung tissues were analyzed. Based on these profiles, a prediction model was created that had a high rate of predictive accuracy for tumor/normal tissue discrimination, presence of nodal metastasis, and survival. The true benefits of both genetic and proteomic assessment of tumors for risk stratification remain to be defined in prospective clinical trials. Nonetheless, the data suggest that these techniques may provide a better assessment of tumor biology than the clinical variables that are currently utilized and potentially could refine the decision-making process regarding the use of adjuvant therapy in NSCLC.
Tumor factors predictive of chemotherapy sensitivity
Since not all NSCLC patients derive a benefit from adjuvant chemotherapy, it would be worthwhile developing markers to identify the patients most likely to profit from specific chemotherapy drugs.
Cisplatin binds to DNA and forms platinum-DNA adducts thus inhibiting DNA replication. The nucleotide excision repair complex is a DNA repair pathway that attends to DNA damage from various factors and plays an important role in chemotherapy resistance. The ERCC 1 (excision repair cross complementation group 1) gene encodes for a protein that belongs to the nucleotide excision repair complex and is involved in the rate limiting step of the complex. In vitro and retrospective clinical studies have linked ERCC1 mRNA expression to platinum resistance [Reed, 2005] . Most of these studies have conducted their analyses through RNA or DNA assessment and could limit the wider applicability of this marker in clinical practice.
Recently Olaussen and colleagues reported results of the IALT Bio study, a retrospective assessment of ERCC1 expression by immunohistochemistry in tumors of patients enrolled on the IALT trial [Olaussen et al. 2006 ]. ERCC1 protein expression was evaluated in paraffin-embedded tumor blocks of 761 patients. Tumors were assigned a semiquantitative H score based on the percentage of positive tumor nuclei and the staining intensity for ERCC1 and then classified as positive or negative. Adjuvant cisplatin-based therapy significantly prolonged survival in patients with ERCC1 negative tumors (HR 0.65, p ¼ 0.002) but not in ERCC1 positive tumors (HR 1.14, p ¼ 0.40). These data suggest that ERCC1 expression could serve as an independent marker predicting benefit or lack thereof from platin-based therapy. These data need to be confirmed in a prospective trial before this marker can be utilized in clinical practice.
Other markers such as BRCA1, RRM1, XRCC3 polymorphisms, are being assessed for sensitivity to different chemotherapy drugs Bepler et al. 2005] . RRM1 (ribonucleotide reductase M1) has been associated with resistance to gemcitabine. SWOG 0720 is a feasibility trial in stage I (T > 2 cm) resected NSCLC. Patients with tumors that have low expression of ERCC1 and RRM1 will receive adjuvant chemotherapy with cisplatin/gemcitabine while those with high expression will not receive chemotherapy.
Assessment of all these markers may actually allow one to customize chemotherapy and improve patient survival by maximizing the efficacy of the adjuvant treatment.
Conclusion
The recent clinical trials assessing chemotherapy after surgical resection of lung cancer have changed clinical practice. There is no doubt that NSCLC patients are living longer as a result of receiving adjuvant treatment. However, it is also clear that patients still die of their disease despite chemotherapy and that some patients may not even require additional treatment after surgery. The lung cancer population is very heterogeneous, thus understanding the molecular makeup of individual tumors is vital in order to determine which patients are at risk for disease relapse and to better select effective adjuvant treatments. It is important to support innovative clinical trials in order to advance our understanding of lung cancer and hopefully achieve a cure for the patients afflicted with this disease.
